| ALIGOS THERAPEUTICS |
| USA |
| Gesundheit |
| US01626L2043 / A40LQ4 |
| 5WK0 (Frankfurt) / ALGS (NASDAQ) |
| FRA:5WK0, ETR:5WK0, 5WK0:GR, NASDAQ:ALGS |
| - |
| https://aligos.com/ |
|
Aligos Therapeutics Inc. is a clinical-stage biotechnology company specializing in the discovery and development of targeted antiviral and liver disease therapies. The firm focuses on unmet medical ne..
>Volltext.. |
| 36.97 Mio. EUR |
| -43.04 Mio. EUR |
| 2.28 Mio. EUR |
| -73.65 Mio. EUR |
| -74.57 Mio. EUR |
| -10.8 EUR |
| 5.23 Mio. EUR |
| 36.27 Mio. EUR |
| -68.27 Mio. EUR |
| 4.51 |
| -58.14% |
| -6.61% |
| - |
| - |
| - |
| - |
| ALIGOS |
| 05.03.26 |
|